1 Prior to the Medicare GLP-1 Bridge, Medicare coverage for weight management medications was largely unavailable, leaving many eligible patients without an affordable route to treatment
doi: 10.1111/acer.12774
However, studies have had contradicting results
The rule covers medical items and services only
The following information was derived from each of the trials, including the publication details (clinical trial number and trial phase, source of funding, author, year of publication, country), participant profiles (age and BMI at baseline, percentage of female, ethnicity, comorbidity), treatment characteristics (sample size, placebo controlled, trial duration, dosage, with or without lifestyle intervention), and outcome measures
We reach for Tesamorelin specifically when InBody visceral fat readings are elevated, when the patient has tried foundation interventions without resolving the abdominal pattern, and when IGF-1 baseline labs make the protocol safe to initiate